Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘CPI-818’

ASH19 Targeted Therapies Preview: This year’s ASH in Orlando is very much dominated by new developments on the immunotherapy front in terms of both T and NK cell therapies, with some passing interest in BTK inhibitors as well.

It’s not always sunny in Florida…

What about targeted therapies and the science behind those developments?

It was not that long ago that these were the main lifeblood of the meeting across many, if not most, hematologic malignancies. How times have changed!

That said, outside of the CARs (T and NK cells), as well as bispecific immunotherapies, and BTK inhibitors there are still some gems to be found amongst the rest of the ASH19 abstracts.

Here we highlight an additional 10 abstracts involving early pipeline areas that encompass some novel targets, new combination approaches, or emerging science.

Please note that the novel targets can take the form of classic targets or IO ones since they didn’t fit in the prior ASH Preview topics already reviewed under separate cover

Curious to find out more about these intriguing selections and get a heads up on additional insights from our ASH19 commentary?Subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Amsterdam – this weekend it’s time to showcase some important updates in hematology from the European Hematology Association (EHA).

It’s really hard not to like continental Europe when you see scenes like this from a major conference:

T cell lymphomas is not a topic we cover very often but it looks like it will receive attention here three times in a month with news from Corvus at ASCO and now an update on the intriguing story on CXCL12-positive AML and PTCL from Kura Oncology.

We’ve been following the latter story for a while now and after the previous looks at the rationale behind the translational data, it’s now time to explore what happens in clinical practice from their ongoing phase 2 clinical trial…

To learn more and get a heads up on our latest oncology insights and conference analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Corvus Pharmaceuticals LogoA biotech company we’ve been following for several years – on what has turned out to be a rollercoaster ride so far – is Corvus Pharmaceuticals (NASDAQ: CRVS).

They were pioneers in targeting the adenosine pathway with their adenosine A2A receptor antagonist,  CPI–444, now known as ciforadenant.

So what’s new at Corvus? It turns out quite a lot.

At ASCO 2019, BSB caught up with Richard A Miller MD, Co-Founder, President, and CEO of Corvus Pharmaceuticals to learn more about their progress and importantly, where they’re headed.

To learn more and get a heads up on our latest oncology insights and conference analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!